Clalit studied symptomatic COVID-19 infections among 600,000 people who received two doses of Pfizer’s vaccine and compared them to an unvaccinated group of the same size, The Wall Street Journal reported Feb. 15. The study included 430,000 participants between ages 16 and 59 and 170,000 participants ages 60 and older, Clalit said.
The study also found that Pfizer’s vaccine reduced cases of severe illness from COVID-19 by 92 percent, according to The Wall Street Journal.
More articles on pharmacy:
36% of Americans forgo medications to pay for essentials, survey says
Sanofi COVID-19 vaccine will not be ready this year, CEO says
Small pharmacies struggling to obtain reimbursement for COVID-19 vaccine administration
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.